Human IL-6 Protein, premium grade
分子别名(Synonym)
IL6,Interleukin-6,BSF2,HSF,IFNB2
表达区间及表达系统(Source)
Human IL-6, premium grade (IL6-H4218) is expressed from human 293 cells (HEK293). It contains AA Val 30 - Met 212 (Accession # NP_000591.1).
Predicted N-terminus: Val 30
重组人IL-6蛋白,premium级(IL6-H4218),专为临床前阶段设计,具有与GMP及重组人IL-6蛋白(GMP-L06H27)相同的活性和性能,可实现从临床前开发到临床阶段的无缝过渡。在原材料安全不是首要任务的早期开发阶段,premium产品为GMP产品提供了一种经济高效的替代品。通过在早期开发阶段使用premium级产品,您可以轻松过渡到临床和商业阶段,而无需重新验证原材料和修改制造工艺。
蛋白结构(Molecular Characterization)
This protein carries no "tag".
The protein has a calculated MW of 20.8 kDa. The protein migrates as 23-29 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
内毒素(Endotoxin)
Less than 0.01 EU per μg by the LAL method.
宿主蛋白残留(Host Cell Protein)
<0.5 ng/µg of protein tested by ELISA.
宿主核酸残留(Host Cell DNA)
<0.02 ng/μg of protein tested by qPCR.
无菌(Sterility)
Negative
支原体(Mycoplasma)
Negative.
纯度(Purity)
>95% as determined by SDS-PAGE.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
白细胞介素6(IL-6)也称为HGF,BSF2,HSF,IFNB2和IL-6,最初被鉴定为B细胞分化因子,是一种多功能细胞因子,可调节免疫反应,造血,急性期反应和炎症反应。它由T细胞、巨噬细胞、单核细胞、成纤维细胞、内皮细胞等分泌,以刺激对创伤的免疫反应,尤其是烧伤或其他导致炎症的组织损伤。白细胞介素6已被证明与白细胞介素6受体和糖蛋白相互作用。IL-6与许多疾病过程有关,例如糖尿病,动脉粥样硬化,抑郁症,阿尔茨海默病,系统性红斑狼疮,前列腺癌和类风湿性关节炎。晚期/转移性癌症患者的血液中IL-6水平较高。因此,有兴趣开发抗IL-6药物作为针对许多这些疾病的治疗方法。
关键字: IL-6;IL-6蛋白;IL-6重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。